MCID: PSR002
MIFTS: 61

Psoriasis malady

Categories: Rare diseases, Skin diseases, Genetic diseases

Aliases & Classifications for Psoriasis

Aliases & Descriptions for Psoriasis:

Name: Psoriasis 12 50 24 29 52 41 3 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:8893
ICD10 33 L40 L40.9
MeSH 42 D011565
NCIt 47 C3346
UMLS 69 C0033860

Summaries for Psoriasis

MedlinePlus : 41 psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. you usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. some people who have psoriasis also get a form of arthritis called psoriatic arthritis. a problem with your immune system causes psoriasis. in a process called cell turnover, skin cells that grow deep in your skin rise to the surface. normally, this takes a month. in psoriasis, it happens in just days because your cells rise too fast. psoriasis can be hard to diagnose because it can look like other skin diseases. your doctor might need to look at a small skin sample under a microscope. psoriasis can last a long time, even a lifetime. symptoms come and go. things that make them worse include infections stress dry skin certain medicines psoriasis usually occurs in adults. it sometimes runs in families. treatments include creams, medicines, and light therapy. nih: national institute of arthritis and musculoskeletal and skin diseases

MalaCards based summary : Psoriasis is related to psoriasis 14, pustular and psoriasis susceptibility 1, and has symptoms including exanthema, pruritus and psoriasiform rash. An important gene associated with Psoriasis is CDSN (Corneodesmosin). The drugs Rayos and Zinc have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and endothelial.

NIH Rare Diseases : 50 psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. the skin on the elbows, knees, scalp, back, face, palms and feet is most often affected, but other parts of the body can be affected as well. a problem with the immune system causes psoriasis. in a process called cell turnover, skin cells that grow deep in the skin rise to the surface. normally, this takes a month. in psoriasis, it happens in just days because the cells rise too fast. although symptoms may come and go, for many, psoriasis is a lifelong condition. infections, stress, dry skin and certain medications may make symptoms worse. psoriasis usually occurs in adults. it sometimes runs in families. treatments include creams, medications and light therapy. last updated: 7/11/2016

CDC : 3 Psoriasis causes patches of thick red skin and silvery scales. Patches are typically found on the elbows, knees, scalp, lower back, face, palms, and soles of feet, but can affect other places (fingernails, toenails, and mouth). The most common type of psoriasis is called plaque psoriasis.Psoriatic arthritis is an inflammatory type of arthritis that eventually occurs in 10% to 20% of people with psoriasis. It is different from more common types of arthritis (such as osteoarthritis or rheumatoid arthritis) and is thought to be related to the underlying problem of psoriasis. Psoriasis and psoriatic arthritis are sometimes considered together as psoriatic disease.

Wikipedia : 71 Psoriasis is a long-lasting autoimmune disease which is characterized by patches of abnormal skin. These... more...

Related Diseases for Psoriasis

Diseases in the Psoriasis family:

Psoriasis 2

Diseases related to Psoriasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 411)
id Related Disease Score Top Affiliating Genes
1 psoriasis 14, pustular 12.4
2 psoriasis susceptibility 1 12.4
3 guttate psoriasis 12.3
4 pustular psoriasis 12.2
5 psoriasis susceptibility 13 12.1
6 psoriasis 2 12.1
7 psoriatic arthritis 12.1
8 psoriasis, protection against 12.1
9 psoriasis 15, pustular 12.0
10 pustulosis palmaris et plantaris 11.9
11 mental retardation and psoriasis 11.8
12 psoriatic juvenile idiopathic arthritis 11.5
13 tranebjaerg svejgaard syndrome 11.5
14 impetigo herpetiformis 11.4
15 pustulosis of palm and sole 11.3
16 arthritis 11.2
17 geographic tongue 11.1
18 parapsoriasis 11.1
19 subacute cutaneous lupus erythematosus 11.0
20 chronic recurrent multifocal osteomyelitis 11.0
21 singleton-merten syndrome 1 10.8
22 singleton-merten syndrome 2 10.7
23 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.7
24 nail disorder, nonsyndromic congenital, 1 10.7
25 temporomandibular ankylosis 10.7
26 primary cutaneous amyloidosis 10.7
27 hamanishi ueba tsuji syndrome 10.3 CDSN HLA-C
28 dermatitis 10.3
29 primary non-gestational choriocarcinoma of ovary 10.3 IL17A IL36RN
30 radial defect robin sequence 10.3 CARD14 IL36RN
31 robin sequence with cleft mandible and limb anomalies 10.3 CARD14 IL36RN
32 omodysplasia 10.3 CCHCR1 CDSN
33 gaucher disease, type i 10.2 FLG HLA-C
34 atopic dermatitis 10.2
35 sarcoidosis 1 10.2 CDSN HLA-C PSORS1C1 PSORS1C2 PSORS1C3
36 small intestine leiomyoma 10.2 FLG KRT17
37 solitary bone cyst 10.1 CDSN FLG IL36RN S100A7
38 papilledema 10.1 IL36RN KRT17
39 skin disease 10.1
40 brachydactyly small stature face anomalies 10.1 FLG KRT17
41 endotheliitis 10.1
42 bullous pemphigoid 10.0
43 alopecia 10.0
44 rheumatoid arthritis 10.0
45 hepatitis 10.0
46 crohn's disease 9.9
47 pemphigus 9.9
48 obesity 9.9
49 alopecia areata 9.9
50 pityriasis rubra pilaris 9.9

Graphical network of the top 20 diseases related to Psoriasis:



Diseases related to Psoriasis

Symptoms & Phenotypes for Psoriasis

UMLS symptoms related to Psoriasis:


exanthema, pruritus, psoriasiform rash

Drugs & Therapeutics for Psoriasis

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Rayos 17 PREDNISONE Horizon Pharma Approved July of 2012

Drugs for Psoriasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 393)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved Phase 4,Phase 3 7440-66-6 32051 23994
2
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
3
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
4
Adalimumab Approved Phase 4,Phase 2,Phase 3,Phase 1 331731-18-1 16219006
5
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 185243-69-0
6
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 378-44-9 9782
7
Infliximab Approved Phase 4,Phase 3,Phase 2 170277-31-3
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
9
Acitretin Approved Phase 4,Phase 3,Phase 2 55079-83-9 6437841 5284513
10
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 624-49-7 637568 5271565
11
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
12
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1 428863-50-7
13
Ustekinumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 815610-63-0
14
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
15
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
16
Acetaminophen Approved Phase 4 103-90-2 1983
17
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
18
Glatiramer Acetate Approved, Investigational Phase 4 147245-92-9 3081884
19
Triamcinolone Approved, Vet_approved Phase 4,Phase 1,Phase 2 124-94-7 31307
20
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
21
Tazarotene Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 118292-40-3 5381
22
Apremilast Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 608141-41-9 11561674
23
Clocortolone Approved Phase 4 34097-16-0, 4828-27-7 5282493 5311052
24
Desoximetasone Approved Phase 4,Phase 3,Phase 2 382-67-2 5311067
25
Guaifenesin Approved, Vet_approved Phase 4,Phase 2,Phase 1 93-14-1 3516
26
Dapsone Approved, Investigational Phase 4 80-08-0 2955
27
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
28
Desonide Approved, Investigational Phase 4 638-94-8 5311066
29
Capsaicin Approved Phase 4 404-86-4 1548943
30
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
31
Calcitriol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 32222-06-3 134070 5280453
32 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
34
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
35
Butyric Acid Experimental Phase 4,Phase 3,Phase 2,Phase 1 107-92-6 264
36 vitamin d Phase 4,Phase 3,Phase 2,Phase 1
37 beta-endorphin Phase 4
38 Amotosalen Phase 4,Phase 2,Early Phase 1
39 Betamethasone Valerate Phase 4,Phase 3,Phase 2,Phase 1 2152-44-5
40 Calcipotriene Phase 4,Phase 3,Phase 2,Phase 1
41 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
42 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
43 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
45 Furocoumarins Phase 4,Phase 2,Early Phase 1
46 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
47 Adrenocorticotropic Hormone Phase 4
48 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
49 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
50 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1292)
id Name Status NCT ID Phase
1 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis Unknown status NCT01223976 Phase 4
2 Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2 Unknown status NCT01443338 Phase 4
3 Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate Unknown status NCT02313922 Phase 4
4 Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis Unknown status NCT02144857 Phase 4
5 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis Unknown status NCT01439425 Phase 4
6 Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4
7 Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness Unknown status NCT00150930 Phase 4
8 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4
9 Quality of Life of Patients With Psoriasis Treated With Methotrexate: Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4
10 A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4
11 The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis Unknown status NCT01088165 Phase 4
12 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy Unknown status NCT01237262 Phase 4
13 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
14 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4
15 Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis Unknown status NCT01939132 Phase 4
16 An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis Completed NCT01555606 Phase 4
17 Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis Completed NCT00195507 Phase 4
18 Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis Completed NCT00924950 Phase 4
19 A Study of Efalizumab in Patients With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies Completed NCT00249808 Phase 4
20 A Study to Evaluate Ustekinumab in Patients With Plaque Psoriasis in Asia-Pacific Countries Completed NCT01677598 Phase 4
21 Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis Completed NCT01012713 Phase 4
22 A Phase IV Clinical Trial to Study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis Completed NCT01373567 Phase 4
23 Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis Completed NCT00990561 Phase 4
24 A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis Completed NCT00852761 Phase 4
25 Dose Ranging Study to Assess the Efficacy and Safety of Acitretin in Severe Plaque Type Psoriasis Completed NCT01039142 Phase 4
26 Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Completed NCT00581100 Phase 4
27 Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept Completed NCT00992394 Phase 4
28 Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray Completed NCT02985736 Phase 4
29 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation Completed NCT01644396 Phase 4
30 A Study to Assess the Clinical Profile of Patients in Spain With Moderate to Severe Psoriasis. Completed NCT01262534 Phase 4
31 Topical Psoriasis Study for Patients Receiving Biologic Therapy Completed NCT02983981 Phase 4
32 The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment Completed NCT01511315 Phase 4
33 Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4
34 Clinical Assessment and Psychosocial Impact of Psoriasis Completed NCT01964443 Phase 4
35 A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp Completed NCT00669214 Phase 4
36 Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis Completed NCT00936065 Phase 4
37 Moderate to Severe Plaque Psoriasis With Scalp Involvement Completed NCT00791765 Phase 4
38 Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis Completed NCT00110981 Phase 4
39 Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects Completed NCT00658606 Phase 4
40 Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis Completed NCT01265823 Phase 4
41 Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp Completed NCT00881868 Phase 4
42 Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis Completed NCT00161655 Phase 4
43 Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet Completed NCT00735787 Phase 4
44 Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy Completed NCT00581555 Phase 4
45 Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis Completed NCT00655564 Phase 4
46 Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis Completed NCT00332332 Phase 4
47 Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings Completed NCT00708708 Phase 4
48 Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis Completed NCT00723437 Phase 4
49 Adalimumab-psoriasis and Small Bowel Lesions Completed NCT01556672 Phase 4
50 Narrow-Band UVB-Therapy in Psoriasis Completed NCT00748020 Phase 4

Search NIH Clinical Center for Psoriasis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Psoriasis

Genetic tests related to Psoriasis:

id Genetic test Affiliating Genes
1 Psoriasis 29 24

Anatomical Context for Psoriasis

MalaCards organs/tissues related to Psoriasis:

39
Skin, T Cells, Endothelial, Neutrophil, Monocytes, Liver, Thyroid

Publications for Psoriasis

Articles related to Psoriasis:

(show top 50) (show all 3118)
id Title Authors Year
1
Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway. ( 27743912 )
2017
2
Polymorphisms in T helper 1 proinflammatory cytokine genes and the risk of psoriasis in a South Indian Tamil cohort. ( 28084669 )
2017
3
Can signal peptide-CUB-EGF domain-containing protein (SCUBE) levels be a marker of angiogenesis in patients with psoriasis? ( 28238185 )
2017
4
A case of erythema multiforme drug eruption associated with erythrodermic psoriasis induced by sofosbuvir and daclatasvir. ( 27757979 )
2017
5
Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients. ( 28496328 )
2017
6
Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review. ( 28521047 )
2017
7
Relapsing polychondritis associated with psoriasis vulgaris successfully treated with adalimumab: A case report with published work review. ( 28266051 )
2017
8
Annular pustular psoriasis in a 14-month-old girl: a therapeutic challenge. ( 27997815 )
2017
9
Xenotransplantation Model of Psoriasis. ( 28063039 )
2017
10
RIG-I antiviral signaling drives interleukin-23 production and psoriasis-like skin disease. ( 28377495 )
2017
11
Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics. ( 28493493 )
2017
12
Overexpression of Drosha, DiGeorge syndrome critical region gene 8 (DGCR8), and Dicer mRNAs in the pathogenesis of psoriasis. ( 28342199 )
2017
13
Isogarcinol Extracted from Garcinia mangostana L. Ameliorates Imiquimod-Induced Psoriasis-like Skin Lesions in Mice. ( 28081600 )
2017
14
PAMs ameliorates the imiquimod-induced psoriasis-like skin disease in mice by inhibition of translocation of NF-I_B and production of inflammatory cytokines. ( 28464025 )
2017
15
Association between mean platelet volume and disease severity in patients with psoriasis and psoriatic arthritis. ( 28507491 )
2017
16
A preliminary study of new single polymorphisms in the T helper type 17 pathway for psoriasis in the Korean population. ( 27774581 )
2017
17
The role of IL-4 in psoriasis. ( 28064550 )
2017
18
CD40 Ligand Is Increased in Mast Cells in Psoriasis and Actinic Keratosis but Less So in Epithelial Skin Carcinomas. ( 28267402 )
2017
19
Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis. ( 28064543 )
2017
20
Psoriasis and osteoporosis: the debate continues. ( 28504373 )
2017
21
Prediction of atopy via total immunoglobulin E levels andskin prick tests in patients with psoriasis. ( 28425249 )
2017
22
The Impact of Age on Psoriasis Health Care in Germany. ( 28079929 )
2017
23
An exploratory study to investigate health-seeking behaviour in patients with psoriasis using framework analysis. ( 28083871 )
2017
24
microRNA-130a Promotes Human Keratinocyte Viability and Migration and Inhibits Apoptosis Through Direct Regulation of STK40-Mediated NF-I_B Pathway and Indirect Regulation of SOX9-Meditated JNK/MAPK Pathway: A Potential Role in Psoriasis. ( 28085489 )
2017
25
Income disparities in healthcare use remain after controlling for healthcare need: evidence from Swedish register data on psoriasis and psoriatic arthritis. ( 28527093 )
2017
26
Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series. ( 28071837 )
2017
27
New Interleukins in Psoriasis and Psoriatic Arthritis Patients: The Possible Roles of Interleukin-33 to Interleukin-38 in Disease Activities and Bone Erosions. ( 28490011 )
2017
28
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). ( 28074446 )
2017
29
Itch intensity in moderate-to-severe plaque psoriasis versus atopic dermatitis: A meta-analysis. ( 28522048 )
2017
30
Differentiation of pityriasis rubra pilaris from plaque psoriasis by dermoscopy. ( 28280914 )
2017
31
Determinants for drug survival of Methotrexate in patients with psoriasis, split for different reasons of discontinuation - Results of the prospective MTX-CAPTURE. ( 28078672 )
2017
32
Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT. ( 28076860 )
2017
33
A newly revealed IL36RN mutation in sibling cases complements our IL36RN mutation statistics for generalized pustular psoriasis. ( 27802907 )
2017
34
MicroRNA138 regulates keratin 17 protein expression to affect HaCaT cell proliferation and apoptosis by targeting hTERT in psoriasis vulgaris. ( 27936398 )
2017
35
Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis. ( 28069297 )
2017
36
Lack of association between CARD10/CARMA3 tag SNPs and psoriasis vulgaris in the southern Chinese population. ( 28301668 )
2017
37
The Investigation of Antimicrobial Peptides Expression and Its Related Interaction with Methotrexate Treatment in Patients with Psoriasis Vulgaris. ( 28067065 )
2017
38
Toll-like receptor (TLR)7 expression in mycosis fungoides and psoriasis: a case-control study. ( 28054376 )
2017
39
Bullous pemphigoid with IgG autoantibodies to the I+3 subunit of laminin 332 associated with psoriasis vulgaris. ( 28468743 )
2017
40
MicroRNA-194 regulates keratinocyte proliferation and differentiation by targeting Grainyhead-like 2 in psoriasis. ( 28040329 )
2017
41
Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: Analysis in patients from Central and Eastern Europe. ( 28506134 )
2017
42
TWEAK mediates inflammation in experimental atopic dermatitis and psoriasis. ( 28530223 )
2017
43
Recent Highlights in Psoriasis Research. ( 28063651 )
2017
44
Follicular Psoriasis: Differentiation from Pityriasis Rubra Pilaris-An Illustrative Case and Review of the Literature. ( 27874201 )
2017
45
Management of psoriatic arthritis (PsA) among cutaneous psoriasis: from pathogenesis to therapy. ( 28534601 )
2017
46
Human S100A7 Induces Mature Interleukin1I+ Expression by RAGE-p38 MAPK-Calpain1 Pathway in Psoriasis. ( 28060905 )
2017
47
Is Psoriasis an autoimmune disease: interpretations from an immunofluorescence based study. ( 28058749 )
2017
48
T helper-2 cytokine/regulatory T-cell gene polymorphisms and their relation with risk of psoriasis in a South Indian Tamil cohort. ( 28027921 )
2017
49
Crusted scabies in a liver transplant patient mimicking rupioid psoriasis. ( 27297820 )
2016
50
Fibroblast Growth Factor 23 and Placental Growth Factor in Patients with Psoriasis and their Relation to Disease Severity. ( 27098624 )
2016

Variations for Psoriasis

Copy number variations for Psoriasis from CNVD:

7 (show all 27)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 107130 17 1225928 31649829 Copy number CCL3L3 Psoriasis
2 107139 17 1225928 31649843 Copy number CCL3L1 Psoriasis
3 107160 17 1242109 31665953 Copy number CCL4L2 Psoriasis
4 110229 17 31562580 31665959 Copy number CCL4L1 Psoriasis
5 209406 6 2614953 31491069 Copy number MICA Psoriasis
6 211355 6 32593131 32665540 Copy number HLA-DRB5 Psoriasis
7 212281 6 3674895 32665540 Copy number HLA-DRB1 Psoriasis
8 212427 6 3795995 32719407 Copy number HLA-DQA1 Psoriasis
9 212447 6 3813334 32742444 Copy number HLA-DQB1 Psoriasis
10 230703 8 1 12700000 Copy number Psoriasis
11 241415 8 6200000 12700000 Copy number Psoriasis
12 241416 8 6200000 12700000 Copy number DEFB103 Psoriasis
13 241417 8 6200000 12700000 Copy number DEFB104 Psoriasis
14 241418 8 6200000 12700000 Copy number DEFB4 Psoriasis
15 241438 8 6200000 12700000 Gain DEFB103 Psoriasis
16 241439 8 6200000 12700000 Gain DEFB104 Psoriasis
17 241440 8 6200000 12700000 Gain DEFB105 Psoriasis
18 241441 8 6200000 12700000 Gain DEFB106 Psoriasis
19 241442 8 6200000 12700000 Gain DEFB107 Psoriasis
20 241443 8 6200000 12700000 Gain DEFB4 Psoriasis
21 241446 8 6200000 12700000 Gain SPAG11 Psoriasis
22 241447 8 6200000 12700000 High copy numbers Psoriasis
23 241468 8 6200000 12700000 Copy number DEFB4 Psoriasis
24 242595 8 7292685 7758729 Large repeat SPAG11 Psoriasis
25 242629 8 7327435 7723985 Large repeat DEFB106 Psoriasis
26 242645 8 7332652 7718770 Large repeat DEFB105 Psoriasis
27 242649 8 7340777 7710648 Large repeat DEFB107 Psoriasis

Expression for Psoriasis

LifeMap Discovery
Genes differentially expressed in tissues of Psoriasis patients vs. healthy controls: 35 (show all 41)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 S100A9 S100 calcium binding protein A9 Skin + 7.14 0.000
2 S100A7 S100 calcium binding protein A7 Skin + 7.06 0.000
3 S100A7A S100 calcium binding protein A7A Skin + 6.53 0.000
4 S100A8 S100 calcium binding protein A8 Skin + 6.48 0.000
5 SPRR2F small proline-rich protein 2F Skin + 6.27 0.000
6 PI3 peptidase inhibitor 3, skin-derived Skin + 6.19 0.000
7 KRT6C keratin 6C, type II Skin + 5.98 0.000
8 SPRR2A small proline-rich protein 2A Skin + 5.97 0.000
9 KRT6A keratin 6A, type II Skin + 5.90 0.000
10 SPRR2B small proline-rich protein 2B Skin + 5.41 0.000
11 KRT6B keratin 6B, type II Skin + 5.39 0.000
12 SPRR2D small proline-rich protein 2D Skin + 5.35 0.000
13 SERPINB3 serpin peptidase inhibitor, clade B (ovalbumin), member 3 Skin + 5.23 0.000
14 GJB2 gap junction protein, beta 2, 26kDa Skin + 4.97 0.000
15 SPRR2C small proline-rich protein 2C (pseudogene) Skin + 4.90 0.000
16 C10orf99 chromosome 10 open reading frame 99 Skin + 4.46 0.000
17 LCE3D late cornified envelope 3D Skin + 4.42 0.000
18 SPRR1A small proline-rich protein 1A Skin + 4.34 0.000
19 LCE3A late cornified envelope 3A Skin + 4.34 0.000
20 AKR1B10 aldo-keto reductase family 1, member B10 (aldose reductase) Skin + 4.33 0.000
21 SPRR1B small proline-rich protein 1B Skin + 4.29 0.000
22 KRT16 keratin 16, type I Skin + 4.27 0.000
23 KYNU kynureninase Skin + 4.26 0.000
24 LCN2 lipocalin 2 Skin + 4.20 0.000
25 SPRR2G small proline-rich protein 2G Skin + 4.12 0.000
26 LCE3E late cornified envelope 3E Skin + 4.12 0.000
27 SERPINB4 serpin peptidase inhibitor, clade B (ovalbumin), member 4 Skin + 3.97 0.000
28 FABP5 fatty acid binding protein 5 (psoriasis-associated) Skin + 3.89 0.000
29 IFI27 interferon, alpha-inducible protein 27 Skin + 3.80 0.000
30 TCN1 transcobalamin I (vitamin B12 binding protein, R binder family) Skin + 3.73 0.000
31 FABP5P2 fatty acid binding protein 5 pseudogene 2 Skin + 3.72 0.000
32 KLK6 kallikrein-related peptidase 6 Skin + 3.54 0.000
33 IL36G interleukin 36, gamma Skin + 3.50 0.000
34 DEFB103B defensin, beta 103B Skin + 3.46 0.000
35 PAMR1 peptidase domain containing associated with muscle regeneration 1 Skin - 3.43 0.000
36 GJB6 gap junction protein, beta 6, 30kDa Skin + 3.38 0.000
37 SPRR2E small proline-rich protein 2E Skin + 3.24 0.000
38 POSTN periostin, osteoblast specific factor Skin - 3.14 0.000
39 CD36 CD36 molecule (thrombospondin receptor) Skin + 3.12 0.000
40 IGFL1 IGF-like family member 1 Skin + 3.11 0.000
41 CACNA1H calcium channel, voltage-dependent, T type, alpha 1H subunit Skin - 3.11 0.000
Search GEO for disease gene expression data for Psoriasis.

Pathways for Psoriasis

GO Terms for Psoriasis

Cellular components related to Psoriasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.17 AREG CCL2 IL17A IL20 IL36A IL36RN

Biological processes related to Psoriasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.55 CCL2 HLA-C IL17A IL36A IL36RN
2 cornification GO:0070268 9.5 CDSN FLG KRT17
3 positive regulation of osteoclast differentiation GO:0045672 9.37 IL17A IL20
4 positive regulation of monocyte chemotaxis GO:0090026 9.26 CCL2 S100A7
5 keratinocyte differentiation GO:0030216 9.13 CDSN FLG S100A7
6 epidermis development GO:0008544 8.92 CDSN FABP5 KRT17 S100A7

Molecular functions related to Psoriasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 interleukin-1 receptor binding GO:0005149 9.16 IL36A IL36RN
2 transition metal ion binding GO:0046914 9.13 FLG S100A7 S100A7A
3 cytokine activity GO:0005125 9.1 AREG CCL2 IL17A IL20 IL36A IL36RN

Sources for Psoriasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....